A study analyzed the differentiation status of CD8+ tumor-infiltrating lymphocytes (TILs) in primary glioma patients to sort out the underlying mechanisms of non-responsiveness to ICB treatment [36]. The gene discussed is CD8A; the disease is neoplasm.